PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Gland Pharma Limited (GLAND.NS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISININE068V01023
SectorHealthcare
IndustryDrug Manufacturers—General

Highlights

Market Cap₹303.93B
EPS₹40.05
PE Ratio46.07
PEG Ratio9.08
Revenue (TTM)₹49.12B
Gross Profit (TTM)₹17.65B
EBITDA (TTM)₹10.34B
Year Range₹861.00 - ₹2,194.00
Target Price₹1,833.56

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Gland Pharma Limited

Performance

Performance Chart

The chart shows the growth of an initial investment of ₹10,000 in Gland Pharma Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%NovemberDecember2024FebruaryMarchApril
-3.84%
60.28%
GLAND.NS (Gland Pharma Limited)
Benchmark (^GSPC)

S&P 500

Returns By Period

Gland Pharma Limited had a return of -9.08% year-to-date (YTD) and 42.08% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-9.08%5.29%
1 month-2.05%-2.47%
6 months8.71%16.40%
1 year42.08%20.88%
5 years (annualized)N/A11.60%
10 years (annualized)N/A10.43%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20241.67%-9.74%4.49%
2023-3.81%-7.71%14.79%8.44%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GLAND.NS is 75, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of GLAND.NS is 7575
Gland Pharma Limited(GLAND.NS)
The Sharpe Ratio Rank of GLAND.NS is 7777Sharpe Ratio Rank
The Sortino Ratio Rank of GLAND.NS is 7373Sortino Ratio Rank
The Omega Ratio Rank of GLAND.NS is 7777Omega Ratio Rank
The Calmar Ratio Rank of GLAND.NS is 7272Calmar Ratio Rank
The Martin Ratio Rank of GLAND.NS is 7575Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Gland Pharma Limited (GLAND.NS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


GLAND.NS
Sharpe ratio
The chart of Sharpe ratio for GLAND.NS, currently valued at 0.79, compared to the broader market-2.00-1.000.001.002.003.000.79
Sortino ratio
The chart of Sortino ratio for GLAND.NS, currently valued at 1.38, compared to the broader market-4.00-2.000.002.004.001.38
Omega ratio
The chart of Omega ratio for GLAND.NS, currently valued at 1.22, compared to the broader market0.501.001.501.22
Calmar ratio
The chart of Calmar ratio for GLAND.NS, currently valued at 0.49, compared to the broader market0.001.002.003.004.005.000.49
Martin ratio
The chart of Martin ratio for GLAND.NS, currently valued at 2.63, compared to the broader market0.0010.0020.0030.002.63
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.79, compared to the broader market-2.00-1.000.001.002.003.001.79
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.61, compared to the broader market-4.00-2.000.002.004.002.61
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.31
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.001.002.003.004.005.001.36
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Gland Pharma Limited Sharpe ratio is 0.79. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
0.79
2.17
GLAND.NS (Gland Pharma Limited)
Benchmark (^GSPC)

Dividends

Dividend History


Gland Pharma Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2024FebruaryMarchApril
-59.46%
-3.53%
GLAND.NS (Gland Pharma Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Gland Pharma Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Gland Pharma Limited was 79.30%, occurring on May 22, 2023. The portfolio has not yet recovered.

The current Gland Pharma Limited drawdown is 59.46%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-79.3%Aug 13, 2021438May 22, 2023
-15.82%Jan 6, 202118Feb 1, 202123Mar 4, 202141
-11.2%Mar 17, 20218Mar 26, 202113Apr 19, 202121
-8.16%May 20, 202123Jun 21, 20216Jun 29, 202129
-7.42%Dec 8, 20208Dec 17, 20204Dec 23, 202012

Volatility

Volatility Chart

The current Gland Pharma Limited volatility is 10.76%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%NovemberDecember2024FebruaryMarchApril
10.76%
3.44%
GLAND.NS (Gland Pharma Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Gland Pharma Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items